Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 793-797

  Prendergast, George C ^a  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGING; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; COST EFFECTIVENESS ANALYSIS; EPIGENETICS; GENE MUTATION; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; NEOPLASM; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

EID: 84883796902     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20909     Document Type: Article

References (13)

1. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005; 235:259-65; PMID:15695622; http://dx.doi.org/10.1148/radiol.2351041662.
2. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336:897- 904; PMID:9070469; http://dx.doi.org/10.1056/NEJM199703273361301.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486.
4. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11323675; http://dx.doi.org/10.1038/35074122.
5. Prendergast GC, Metz R, Muller AJ. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol 2010; 176:2082- 7; PMID:20228228; http://dx.doi.org/10.2353/ajpath.2010.091173.
6. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-92; PMID:22397650; http://dx.doi.org/10.1056/NEJMoa1113205.
7. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223.
8. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626.
9. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.1038/nm.2438.
10. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 2005; 65:8065-8; PMID:16166276; http://dx.doi.org/10.1158/0008-5472.CAN-05-2213.
11. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011; 108:7142-7; PMID:21482773; http://dx.doi.org/10.1073/pnas.1016569108.
12. Weiner LM. Cancer immunotherapy-the endgame begins. N Engl J Med 2008; 358:2664-5; PMID:18565858; http://dx.doi.org/10.1056/NEJMp0803663.
13. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889- 900; PMID:18317452; http://dx.doi.org/10.1038/onc.2008.35.